(ALGN) Align Technology - Ratings and Ratios

Align Technology, Inc. is a global medical device company that has revolutionized orthodontic treatment with its innovative products. The company designs, manufactures, and markets Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services. These products are distributed in the United States, Switzerland, and internationally, catering to a broad range of dental and orthodontic needs. The Clear Aligner segment offers comprehensive solutions for treating malocclusion in adults, teens, and younger patients, including specific packages like Invisalign First Phase I and Comprehensive Phase 2 for children aged six to ten. This segment also provides various ancillary products such as retention devices, whitening systems, and 3D printed orthodontic devices. The Imaging Systems and CAD/CAM Services segment includes the iTero intraoral scanning system, which offers a single hardware platform for restorative and orthodontic procedures, as well as software solutions for digital records storage, diagnosis, and fabrication of models and retainers.

Align Technology, Inc. (NASDAQ: ALGN) is a leader in the digital orthodontics and restorative dentistry market. The company was incorporated in 1997 and is headquartered in the United States. Its products and services have transformed the dental industry by providing precise, digital solutions for orthodontic treatment and restorative procedures. The companys market capitalization is approximately $12.6 billion, with a price-to-earnings ratio of 30.64 and a forward P/E of 17.51, indicating growth expectations. The companys technical indicators show an average 20-day volume of 1,276,450 shares, with a last price of $173.87. The short-term moving average (SMA 20) is $162.50, while the SMA 50 and SMA 200 are $174.32 and $214.43, respectively. The Average True Range (ATR) is 7.90, reflecting moderate volatility.

3-Month Forecast: Based on the technical and fundamental data, Align Technology, Inc. (ALGN) is expected to experience a period of consolidation in the near term. The SMA 20 is currently below the SMA 50, suggesting short-term weakness, but the proximity of these moving averages indicates potential stability. With an ATR of 7.90, the stock is likely to trade within a range of $165 to $185 over the next three months. The fundamental strength, supported by a market cap of $12.6 billion and a return on equity of 10.94%, suggests that the stock may rebound towards the SMA 200 level of $214.43 in the medium term, driven by continued demand for digital orthodontic solutions and the companys strong market position.